Analyses of P16
EGFR
Lung cancer
Methylation
SNPs
p16INK4a
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
22
07
2022
accepted:
23
09
2022
pubmed:
16
11
2022
medline:
3
2
2023
entrez:
15
11
2022
Statut:
ppublish
Résumé
The aim of this study was to examine the methylation status of p16 Formalin-fixed and paraffin-embedded (FFPE) DNA samples extracted from 22 NSCLC patients were analyzed with methylation-specific polymerase chain reaction (PCR) method to obtain promoter methylation profile. The same cohort was genotyped for - 216G > T, -191 C > A, and 181,946 C > T EGFR SNPs. There was a significant association between methylated p16 High frequency of methylation of the p16
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to examine the methylation status of p16
METHODS
METHODS
Formalin-fixed and paraffin-embedded (FFPE) DNA samples extracted from 22 NSCLC patients were analyzed with methylation-specific polymerase chain reaction (PCR) method to obtain promoter methylation profile. The same cohort was genotyped for - 216G > T, -191 C > A, and 181,946 C > T EGFR SNPs.
RESULTS
RESULTS
There was a significant association between methylated p16
CONCLUSION
CONCLUSIONS
High frequency of methylation of the p16
Identifiants
pubmed: 36378420
doi: 10.1007/s11033-022-07982-1
pii: 10.1007/s11033-022-07982-1
doi:
Substances chimiques
Cyclin-Dependent Kinase Inhibitor p16
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
971-979Subventions
Organisme : Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
ID : 175056
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Siegel RL, Miller KD, Cancer statistics (2020) 2020;70(1):7–30
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M et al (2018) Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356–387
doi: 10.1016/j.ejca.2018.07.005
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68(6):394–424
doi: 10.3322/caac.21492
Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K et al (2019) Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manage Res 11:943–953
doi: 10.2147/CMAR.S187317
Pinto JA, Vallejos CS, Raez LE, Mas LA, Ruiz R, Torres-Roman JS et al (2018) ;3(3):e000344
Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH (1995) Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18 + years–an analysis of 1,714 consecutive patients. J Clin oncology: official J Am Soc Clin Oncol 13(5):1215–1220
doi: 10.1200/JCO.1995.13.5.1215
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic proceedings. ;83(5):584 – 94
Xia W, Yu X, Mao Q, Xia W, Wang A, Dong G et al (2017) Improvement of survival for non-small cell lung cancer over time. OncoTargets and therapy 10:4295–4303
doi: 10.2147/OTT.S145036
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139
doi: 10.1056/NEJMoa040938
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, vol 304. Science, New York, NY, pp 1497–1500. 5676
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36):13306–13311
doi: 10.1073/pnas.0405220101
Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L et al (2014) 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. ;25(8):1475-84
Amador ML, Oppenheimer D, Perea S, Maitra A, Cusatis G, Iacobuzio-Donahue C et al (2004) An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64(24):9139–9143
doi: 10.1158/0008-5472.CAN-04-1036
Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K et al (2008) Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 8(2):129–138
doi: 10.1038/sj.tpj.6500444
Liu G, Cheng D, Ding K, Le Maitre A, Liu N, Patel D et al (2012) Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer. J Thorac oncology: official publication Int Association Study Lung Cancer 7(2):316–322
doi: 10.1097/JTO.0b013e31824166c1
Jung M, Cho BC, Lee CH, Park HS, Kang YA, Kim SK et al (2012) EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Yonsei Med J 53(6):1128–1135
doi: 10.3349/ymj.2012.53.6.1128
Jurišić V, Obradovic J, Pavlović S, Djordjevic N (2018) Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation. Anal Cell Pathol (Amst). ; 14;2018:6192187. doi: https://doi.org/10.1155/2018/6192187
Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P et al (2007) Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 4(4):e125
doi: 10.1371/journal.pmed.0040125
Ma F, Sun T, Shi Y, Yu D, Tan W, Yang M et al (2009) Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung cancer (Amsterdam Netherlands) 66(1):114–119
doi: 10.1016/j.lungcan.2008.12.025
Yuan F, Cao X, Zhang YH, Chen L, Huang T, Li Z et al (2022) Identification of Novel Lung Cancer Driver Genes Connecting Different Omics Levels With a Heat Diffusion Algorithm. Front cell Dev biology 10:825272
doi: 10.3389/fcell.2022.825272
Zhou C, Hu H, Zheng Z, Chen C, Li Y, Li B et al (2019) Association between GPX3 promoter methylation and malignant tumors: A meta-analysis. Pathol Res Pract 215(7):152443
doi: 10.1016/j.prp.2019.152443
Zhang Z, Xin S, Gao M, Cai Y (2017) Promoter hypermethylation of MGMT gene may contribute to the pathogenesis of gastric cancer: A PRISMA-compliant meta-analysis. Medicine 96(17):e6708
doi: 10.1097/MD.0000000000006708
Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E et al (1998) Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95(20):11891–11896
doi: 10.1073/pnas.95.20.11891
Li X, Mao W, Guo D, Xu H (2019) Clinicopathological Significance and Diagnostic Value of DLEC1 Hypermethylation in Lung Cancer: A Meta-analysis. J Nippon Med School = Nippon Ika Daigaku zasshi 86(2):62–69
doi: 10.1272/jnms.JNMS.2019_86-201
Nikolic N, Carkic J, Ilic Dimitrijevic I, Eljabo N, Radunovic M, Anicic B et al (2018) P14 methylation: an epigenetic signature of salivary gland mucoepidermoid carcinoma in the Serbian population. Oral surgery, oral medicine, oral pathology and oral radiology. 125:52–581
Hao X, Luo H, Krawczyk M, Wei W, Wang W, Wang J et al (2017) DNA methylation markers for diagnosis and prognosis of common cancers. Proc Natl Acad Sci USA 114(28):7414–7419
doi: 10.1073/pnas.1703577114
Gu J, Wen Y, Zhu S, Hua F, Zhao H, Xu H et al (2013) Association between P(16INK4a) promoter methylation and non-small cell lung cancer: a meta-analysis. PLoS ONE 8(4):e60107
doi: 10.1371/journal.pone.0060107
Wang BH, Li YY, Han JZ, Zhou LY, Lv YQ, Zhang HL et al (2017) Gene methylation as a powerful biomarker for detection and screening of non-small cell lung cancer in blood. Oncotarget 8(19):31692–31704
doi: 10.18632/oncotarget.15919
Tuo L, Sha S, Huayu Z, Du K (2018) P16(INK4a) gene promoter methylation as a biomarker for the diagnosis of non-small cell lung cancer: An updated meta-analysis. Thorac cancer 9(8):1032–1040
doi: 10.1111/1759-7714.12783
Xing XB, Cai WB, Luo L, Liu LS, Shi HJ, Chen MH (2013) The Prognostic Value of p16 Hypermethylation in Cancer: A Meta-Analysis. PLoS ONE 8(6):e66587
doi: 10.1371/journal.pone.0066587
Jurisic V, Vukovic V, Obradovic J, Gulyaeva LF, Kushlinskii NE, Djordjević (2020) N:. EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis. J Oncol 2020:1973241
doi: 10.1155/2020/1973241
Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H et al (2014) The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac oncology: official publication Int Association Study Lung Cancer 9(11):1618–1624
doi: 10.1097/JTO.0000000000000334
Obradović J, Djordjević N, Tošic N, Mrdjanović J, Stanković B, Stanić J et al (2016) Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 37(8):10479–10486
doi: 10.1007/s13277-016-4930-4
Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93(18):9821–9826
doi: 10.1073/pnas.93.18.9821
Obradovic J, Jurisic V, Tosic N, Mrdjanovic J, Perin B, Pavlovic S et al (2013) Optimization of PCR conditions for amplification of GC-Rich EGFR promoter sequence. J Clin Lab Anal 27(6):487–493
doi: 10.1002/jcla.21632
Metsalu T, Vilo J (2015) ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res 43(W1):W566–W570
doi: 10.1093/nar/gkv468
Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S et al (2021) The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res 49(D1):D605–d12
doi: 10.1093/nar/gkaa1074
Billard-Sandu C, Tao YG, Sablin MP, Dumitrescu G, Billard D, Deutsch E (2020) CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology -. Head and Neck Surgery 277(5):1273–1280
Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, Pakzad I, Salehiniya H (2015) The incidence and mortality of lung cancer and their relationship to development in Asia. Translational lung cancer research 4(6):763–774
Soh J, Toyooka S, Matsuo K, Yamamoto H, Wistuba II, Lam S et al (2015) Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. Oncol Lett 10(3):1775–1782
doi: 10.3892/ol.2015.3414
Wei B, Wu F, Xing W, Sun H, Yan C, Zhao C et al (2021) A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer. Sci Rep 11(1):16782
doi: 10.1038/s41598-021-96242-6
Manser R, Lethaby A, Irving LB, Stone C, Byrnes G, Abramson MJ et al (2013) Screening for lung cancer. Cochrane Database Syst Rev 2013(6):Cd001991
Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F et al (2013) Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 368(21):1980–1991
doi: 10.1056/NEJMoa1209120
Zappa C, Mousa SA (2016) Non-small cell lung cancer: current treatment and future advances. Translational lung cancer research 5(3):288–300
doi: 10.21037/tlcr.2016.06.07
Rauch TA, Wang Z, Wu X, Kernstine KH, Riggs AD, Pfeifer GP (2012) DNA methylation biomarkers for lung cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 33(2):287–296
doi: 10.1007/s13277-011-0282-2